Additionally, a phase 1/2 clinical trial evaluated the anti -PDL1 durvalumab combined with the immunomodulator lenalidomide in patients with aggressive or refractory/advanced cutaneous T-cell lymphoma and determined the safety and efficacy of this regimen [32]. Here, CD274 is linked to primary cutaneous T-cell non-Hodgkin lymphoma.